Peregrine Regains Compliance With NASDAQ Minimum Bid Price

Peregrine Regains Compliance With NASDAQ Minimum Bid Price Listing
Requirement 
TUSTIN, CA -- (Marketwire) -- 12/11/12 --  Peregrine Pharmaceuticals
(NASDAQ: PPHM) today announced that it has received a letter from The
NASDAQ Stock Market LLC notifying the company that it has regained
full compliance with the NASDAQ Capital Market's minimum bid price
continued listing requirement.  
The letter received today noted that as of December 10, 2012, the
company evidenced a closing bid price of its common stock in excess
of the $1.00 minimum requirement for at least ten consecutive trading
days. Accordingly, the company has regained compliance with NASDAQ
Marketplace Rule 5550(a)(2) and the matter is closed. 
About Peregrine Pharmaceuticals, Inc.
 Peregrine Pharmaceuticals,
Inc. is a biopharmaceutical company with a portfolio of innovative
monoclonal antibodies in clinical trials, focused on the treatment
and diagnosis of cancer. The company is pursuing multiple clinical
programs in cancer with its lead product candidate bavituximab and
novel brain cancer agent Cotara(R). Peregrine also has in-house cGMP
manufacturing capabilities through its wholly-owned subsidiary Avid
Bioservices, Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and outside customers.
Additional information about Peregrine can be found at
www.peregrineinc.com.  
Contact: 
Christopher Keenan or Jay Carlson 
Peregrine Pharmaceuticals, Inc. 
(800) 987-8256 
info@peregrineinc.com 
 
 
Press spacebar to pause and continue. Press esc to stop.